Thrombolytically active non-glycosylated protein
    1.
    发明授权
    Thrombolytically active non-glycosylated protein 失效
    紫外线活性非糖蛋白

    公开(公告)号:US5223256A

    公开(公告)日:1993-06-29

    申请号:US585129

    申请日:1990-09-28

    摘要: A new thrombolytically active protein is not glycosylated and consists of the following amino acid sequence: ##STR1## or said amino acid sequence with an additional N-terminal methionine. DNA sequences encoding the thrombolytically active, non-glycosylated protein and pharmaceutical compositions containing said protein are also disclosed. The protein possesses particularly favorable properties when used to dissolve blood clots.

    摘要翻译: PCT No.PCT / EP90 / 00194 Sec。 371 1990年9月28日第 102(e)1990年9月28日PCT PCT 1990年2月6日PCT公布。 第WO90 / 09437号公报 日期8月23日,1990.A新血栓溶解活性蛋白未被糖基化,它包括以下氨基酸序列组成:1SYQGNSDCYFGNGSAYRGTHSLTESGASCL PWNSMILIGKVYTAQNPSAQ 51ALGLGKHNYCRNPDGDAKPWCHVLKNRRLT WEYCDVPSCSTCGLRQYSQP 101QFRIKGGLFADIASHPWQAAIFAKHRRSPG ERFLCGGILISSCWILSAAH 151CFQERFPPHHLTVILGRTYRVVPGEEEQKF EVEKYIVHKEFDDDTYDNDI 201ALLQLKSDSSRCAQESSVVRTVCLPPADLQ LPDWTECELSGYGKHEALSP 251FYSERLKEAHVRLYPSSRCTSQHLLNRTVT DNMLCAGDTRSGGPQANLHD 301ACQGDSGGPLVCLNDGRMTLVGIISWGLGC GQKDVPGVYTKVTNYLDWIR 351DNMRP或所述具有附加的N末端氨基酸序列 甲硫氨酸 还公开了编码血栓溶解活性的非糖基化蛋白质的DNA序列和含有所述蛋白质的药物组合物。 当用于溶解血块时,蛋白质具有特别有利的特性。

    Use of recombinant inhibitor from Erythrina caffra for purifying serine
proteases
    4.
    发明授权
    Use of recombinant inhibitor from Erythrina caffra for purifying serine proteases 失效
    使用Erythrina caffra的重组抑制剂来纯化丝氨酸蛋白酶

    公开(公告)号:US5958722A

    公开(公告)日:1999-09-28

    申请号:US702703

    申请日:1996-09-13

    摘要: Process for purifying serine proteases from a protein mixture by binding the serine protease to an immobilized polypeptide with the activity of an inhibitor DE-3 from Erythrina caffra, removing unbound components from the protein mixture, detaching the serine protease from the inhibitor and separating the immobilized inhibitor from the soluble serine protease and isolating serine protease which is characterized in that a polypeptide is used as the polypeptide which is the product of a prokaryotic or eukaryotic expression of an exogenous nucleic acid. This inhibitor is distinguished by an improved specific activity and is particularly suitable for the purification of plasminogen activators such as tissue plasminogen activators (t-PA and derivatives).

    摘要翻译: PCT No.PCT / EP95 / 00926 Sec。 371日期1996年9月13日 102(e)1996年9月13日PCT PCT 1995年3月13日PCT公布。 公开号WO95 / 25168 日期1995年9月21日从蛋白质混合物中纯化丝氨酸蛋白酶的方法,通过将丝氨酸蛋白酶与来自Erythrina caffra的抑制剂DE-3的活性结合到固定化多肽上,从蛋白质混合物中除去未结合的成分,将丝氨酸蛋白酶从 将固定化的抑制剂与可溶性丝氨酸蛋白酶分离并分离丝氨酸蛋白酶,其特征在于使用多肽作为外源核酸的原核或真核表达产物的多肽。 该抑制剂的特征在于改善的比活性,特别适用于纤维蛋白溶酶原激活剂如组织纤溶酶原激活剂(t-PA和衍生物)的纯化。

    Mutant of the Erythrina caffra type inhibitor and the use of the said
mutant for purifying serine proteases
    5.
    发明授权
    Mutant of the Erythrina caffra type inhibitor and the use of the said mutant for purifying serine proteases 失效
    Erythrina caffra型抑制剂的突变体和所述突变体用于纯化丝氨酸蛋白酶的用途

    公开(公告)号:US5973118A

    公开(公告)日:1999-10-26

    申请号:US943814

    申请日:1997-10-03

    摘要: A polypeptide which has the activity of an inhibitor DE-3 from Erythrina caffra and which reversibly and selectively binds serine proteases from a protein mixture is obtainable by culturing prokaryotic or eukaryotic host cells which have been transformed or transfected with a nucleic acid that codes for the said polypeptide in a manner that allows the host cells to express the said polypeptide under suitable nutrient conditions and isolating the said polypeptide, wherein the polypeptide has an amino acid sequence which is functionally analogous to SEQ ID NO:2, has a partial region that is more than 85% homologous to the region of amino acids 39-139 of this sequence, has two disulfide bridges and begins N-terminally with SEQ ID NO:4 or with a SEQ ID NO:4 extended N-terminally by methionine and has a binding capacity for tissue plasminogen activators of 1.25 MU/ml and more and is particularly suitable for purifying plasminogen activators such as tissue plasminogen activators (t-PA and derivatives).

    摘要翻译: 通过培养原核或真核宿主细胞获得具有来自艾瑞氏菌(Erythrina caffra)的抑制剂DE-3并且可逆地和选择性地结合蛋白质混合物的丝氨酸蛋白酶的多肽,所述原核或真核宿主细胞已经用编码 所述多肽以允许宿主细胞在合适的营养条件下表达所述多肽并分离所述多肽的方式,其中所述多肽具有功能上类似于SEQ ID NO:2的氨基酸序列,其部分区域是 与该序列的氨基酸39-139的区域同源超过85%具有两个二硫键,并与SEQ ID NO:4进行N-末端或与蛋氨酸N-末端扩增的SEQ ID NO:4,并具有 组织纤溶酶原激活剂的结合能力为1.25 MU / ml以上,特别适用于纯化纤溶酶原激活剂如组织纤溶酶原激活剂(t-PA和de rivatives)。